India’s Central Drugs Standard Control Organization (CDSCO) has put out an alert on Abbott Laboratories Inc.'s bioresorbable drug-eluting coronary stent, Absorb GT1 BVS, in the backdrop of global concerns of over-elevated rates of major adverse cardiac events associated with the product.
“Based on the three years’ clinical data analysis from ABSORB II, it has been observed that there is an over-elevated...